AU2009225441B2 - Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase - Google Patents

Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase Download PDF

Info

Publication number
AU2009225441B2
AU2009225441B2 AU2009225441A AU2009225441A AU2009225441B2 AU 2009225441 B2 AU2009225441 B2 AU 2009225441B2 AU 2009225441 A AU2009225441 A AU 2009225441A AU 2009225441 A AU2009225441 A AU 2009225441A AU 2009225441 B2 AU2009225441 B2 AU 2009225441B2
Authority
AU
Australia
Prior art keywords
compound
piperidin
phenyl
oxo
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2009225441A
Other languages
English (en)
Other versions
AU2009225441A1 (en
Inventor
Girish A R
Bharathiraja Ainan
Hariharasubramanian Ayyamperumal
Alexander Bischoff
P. Bala Koteswara Rao
Ganesh Prabhu
Hosahalli Subramanya
Kumar Sundaresan
Srinivas Tatiparthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forest Laboratories Holdings ULC
Original Assignee
Forest Laboratories Holdings ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories Holdings ULC filed Critical Forest Laboratories Holdings ULC
Publication of AU2009225441A1 publication Critical patent/AU2009225441A1/en
Application granted granted Critical
Publication of AU2009225441B2 publication Critical patent/AU2009225441B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2009225441A 2008-03-20 2009-03-20 Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase Expired - Fee Related AU2009225441B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN575/KOL/2008 2008-03-20
IN575KO2008 2008-03-20
US4948008P 2008-05-01 2008-05-01
US61/049,480 2008-05-01
PCT/US2009/037835 WO2009117676A2 (en) 2008-03-20 2009-03-20 Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase

Publications (2)

Publication Number Publication Date
AU2009225441A1 AU2009225441A1 (en) 2009-09-24
AU2009225441B2 true AU2009225441B2 (en) 2012-12-13

Family

ID=41089526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009225441A Expired - Fee Related AU2009225441B2 (en) 2008-03-20 2009-03-20 Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase

Country Status (14)

Country Link
US (1) US8129376B2 (enExample)
EP (1) EP2268143A4 (enExample)
JP (1) JP2011518774A (enExample)
KR (1) KR20100134680A (enExample)
CN (1) CN102036558A (enExample)
AU (1) AU2009225441B2 (enExample)
BR (1) BRPI0909183A2 (enExample)
CA (1) CA2719000A1 (enExample)
IL (1) IL208232A0 (enExample)
MX (1) MX2010010241A (enExample)
NZ (1) NZ588633A (enExample)
RU (1) RU2010142937A (enExample)
WO (1) WO2009117676A2 (enExample)
ZA (1) ZA201007252B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051244A1 (ja) 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
US8642583B2 (en) 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
SG182662A1 (en) 2010-01-28 2012-08-30 Harvard College Compositions and methods for enhancing proteasome activity
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
NO2686520T3 (enExample) 2011-06-06 2018-03-17
FR3000491B1 (fr) * 2012-09-27 2015-08-28 Univ Lille Ii Droit & Sante Composes utilisables dans le traitement des infections mycobacteriennes
CN103772267A (zh) * 2012-10-24 2014-05-07 常州化学研究所 一种二苯胺制备咔唑的方法
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
SG11201607920RA (en) 2014-04-04 2016-10-28 X Rx Inc Substituted spirocyclic inhibitors of autotaxin
BR112016024473A2 (pt) * 2014-04-23 2018-01-23 X Rx Inc composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição
US20160047307A1 (en) * 2014-08-15 2016-02-18 General Electric Company Power train architectures with low-loss lubricant bearings and low-density materials
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
US11384081B2 (en) 2016-09-20 2022-07-12 Centre Leon Berard Benzoimidazole derivatives as anticancer agents
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020514293A (ja) 2017-01-06 2020-05-21 ユマニティ セラピューティクス，インコーポレーテッド 神経障害を治療する方法
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN107663184A (zh) * 2017-11-15 2018-02-06 上海皓伯化工科技有限公司 一种N‑Boc‑4‑羟基哌啶的合成方法
EP3768269B1 (en) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
US10919885B2 (en) 2018-04-25 2021-02-16 Yumanity Therapeutics, Inc. Compounds and uses thereof
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
MX2021008903A (es) * 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CA3148310A1 (en) * 2019-09-13 2021-03-18 Jun Qi Kdm inhibitors and uses thereof
CN110845396B (zh) * 2019-11-07 2023-01-20 宿迁联盛科技股份有限公司 一种2,2,6,6-四甲基-4-哌啶胺类化合物的制备方法
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074283A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6659090A (en) 1989-11-16 1991-06-13 Warner-Lambert Company Acat inhibitors
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
CA2398940C (en) 2000-02-24 2012-02-21 Xenon Genetics, Inc. Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
DE60134995D1 (de) 2000-09-26 2008-09-04 Xenon Pharmaceuticals Inc Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
KR20050045927A (ko) 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
MX2007003319A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
WO2008157844A1 (en) * 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
JPWO2009119537A1 (ja) * 2008-03-26 2011-07-21 第一三共株式会社 ヒドロキシキノキサリンカルボキサミド誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074283A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
ZA201007252B (en) 2011-12-28
US20090239810A1 (en) 2009-09-24
KR20100134680A (ko) 2010-12-23
EP2268143A4 (en) 2012-06-27
AU2009225441A1 (en) 2009-09-24
RU2010142937A (ru) 2012-04-27
MX2010010241A (es) 2010-12-06
NZ588633A (en) 2012-03-30
BRPI0909183A2 (pt) 2015-08-25
IL208232A0 (en) 2010-12-30
EP2268143A2 (en) 2011-01-05
US8129376B2 (en) 2012-03-06
CN102036558A (zh) 2011-04-27
WO2009117676A3 (en) 2010-01-07
WO2009117676A2 (en) 2009-09-24
JP2011518774A (ja) 2011-06-30
CA2719000A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
AU2009225441B2 (en) Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase
WO2010075356A1 (en) Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
AU2009225513C1 (en) Novel piperazine derivatives as inhibitors of stearoyl-CoA desaturase
WO2008157844A1 (en) Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
TWI295287B (en) Benzoyl-piperazine derivatives
CN101198604A (zh) Npy拮抗剂、及其制备和应用
IL173802A (en) Adamantane, azabicyclo-octane and nonane derivatives, process for their preparation and their use for the preparation of pharmaceutical compositions suitable for inhibiting dpp-iv
WO2006132436A1 (ja) 複素環化合物
NZ530202A (en) Piperidine derivatives useful as modulators of chemokine receptor activity
WO2001092227A1 (en) Chemical compounds
CA2722811A1 (en) Pyrazole compounds as ccr1 antagonists
US20040266823A1 (en) Novel piperidine derivatives as modulators of chemokine receptors
EP1448524A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
US20040122049A1 (en) Novel piperidine derivatives as modulators of chemokine receptor
AU2002349840A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee